Grundläggande statistik
| CIK | 1822359 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DocGo Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 11, 2026 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission |
|
| May 11, 2026 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of May 7, 2026 (the “Effective Date”), by and between Norman Rosenberg (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). As of the Effective Date, this Agreement amends and restates in its entirety that Executive Employme |
|
| May 11, 2026 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| May 11, 2026 |
Exhibit 99.1 DocGo Announces First Quarter 2026 Results Company Increases 2026 Revenue Guidance Based on Strong Demand for Virtual Care Services Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, May 11th, 2026 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, t |
|
| May 11, 2026 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of May 7, 2026 (the “Effective Date”), by and between Lee Bienstock (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). As of the Effective Date, this Agreement amends and restates in its entirety that Executive Employment |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 11, 2026 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of May 7, 2026 (the “Effective Date”), by and between Stephen Sugrue (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). As of the Effective Date, this Agreement amends and restates in its entirety that Executive Employment |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2026 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 22, 2026 |
REPORT 2025 ANNUAL LEADING THE PROACTIVE HEALTHCARE REVOLUTIONBOARD OF DIRECTORS EXECUTIVE OFFICERS Stephen K. |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 17, 2026 |
As filed with the Securities and Exchange Commission on March 17, 2026 As filed with the Securities and Exchange Commission on March 17, 2026 Registration No. |
|
| March 17, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 DocGo Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.0001 per share 457(a) 5,747,461 $ 0.63 $ 3,620,900.43 0.0001381 $ 500.05 Total Offering Amounts |
|
| March 16, 2026 |
DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR PERFORMANCE STOCK UNIT AWARD Exhibit 10.17 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR PERFORMANCE STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the target number of performance stock units (“PSUs”) specified below (the “Award”) as performance-based Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each |
|
| March 16, 2026 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| March 16, 2026 |
Exhibit 99.1 DocGo Announces Fourth Quarter and Full Year 2025 Results Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives Company Has Initiated a Formal Process to Explore Strategic Alternatives to Maximize Shareholder Value Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, N |
|
| March 16, 2026 |
FIRST AMENDMENT AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.19 FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) dated as of November 25, 2025, is entered into by and among DOCGO INC., a Delaware corporation and any other party identified on the signature pages hereto as a “Borrower” (each a “Borrower” and collectively, jointly and severally, the “Borrowers”), certain subsidiarie |
|
| March 16, 2026 |
Exhibit 21.1 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2025 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United States Ambulnz Community Partners Ltd England and Wales |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396 |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 16, 2026 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 26, 2026 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 12, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi |
|
| November 10, 2025 |
Exhibit 99.1 DocGo Announces Third Quarter 2025 Results Company Achieves Record Volumes Across All Major Business Lines Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, November 10, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced financi |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi |
|
| November 10, 2025 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following provides information regarding certain financial measures used by DocGo Inc. (the “Company”) that are not calculated or presented in accordance with generally accepted accounting principles (“GAAP”). The Company has provided these non-GAAP measures as supplemental information and in addition to financial measures presented by the Company th |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 20, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or o |
|
| October 21, 2025 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of October 20, 2025 among Ambulnz Holdings, LLC, STMD Merger Company, LLC, SteadyMD, Inc., and Shareholder Representative Services LLC, as the ISP Representative TABLE OF CONTENTS Article 1 THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Effective Time 2 Section 1.3 Effects of the Merger 3 Section 1.4 Organizational Documents 3 |
|
| October 20, 2025 |
Exhibit 99.1 DocGo Acquires Virtual Care Platform SteadyMD, Expands Telehealth Services Across all 50 States Strategic Acquisition Combines DocGo’s Last Mile Healthcare Delivery Capabilities With SteadyMD’s Virtual Care Platform; SteadyMD Is Expected To Generate Approximately $25 Million in Revenue in 2025* NEW YORK, NY, October 20th, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 20, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 7, 2025 |
Exhibit 10.1 Execution Version AMENDED AND RESTATED CREDIT AGREEMENT Dated as of August 7, 2025 among DOCGO INC., as the Borrower, THE SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, CITIBANK, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and THE LENDERS PARTY HERETO ************************************************ CITIBANK, N.A., as Sole Lead Arranger and Sole Book |
|
| August 7, 2025 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| August 7, 2025 |
Exhibit 99.1 DocGo Announces Second Quarter 2025 Results Company Reiterates 2025 Revenue and Adjusted EBITDA Guidance, Increases Total Cash Balance to $128.7 Million, Signs New Contracts Across All Business Verticals Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, August 7th, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider |
|
| June 18, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 12, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| May 8, 2025 |
Exhibit 99.1 DocGo Announces First Quarter 2025 Results Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, May 8th, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-ena |
|
| May 8, 2025 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission |
|
| April 24, 2025 |
ANNUAL REPORT LEADING THE PROACTIVE HEALTHCARE REVOLUTION 2024BOARD OF DIRECTORS EXECUTIVE OFFICERS Stephen K. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 28, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) DocGo Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 pe |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 27, 2025 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| February 27, 2025 |
Exhibit 21.1 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2024 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United States Ambulnz Community Partners Ltd England and Wales |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396 |
|
| February 27, 2025 |
Exhibit 19.1 INSIDER TRADING POLICY (dated April 24, 2023) I. INTRODUCTION DocGo Inc. (the “Company” or “DocGo”) is listed on the Nasdaq Stock Market (the “Nasdaq”), and is subject to its rules, as well as the rules and regulations of the Securities and Exchange Commission (“SEC”). U.S. Federal and state laws prohibit buying, selling, gifting or making other transfers of securities by persons who |
|
| February 27, 2025 |
tice and Agreement under the DocGo Inc. 2021 Stock Incentive Plan. Exhibit 10.21 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR PERFORMANCE STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the target number of performance stock units (“PSUs”) specified below (the “Award”) as performance-based Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi |
|
| February 27, 2025 |
Exhibit 99.1 DocGo Announces Fourth Quarter and Full-Year 2024 Results Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, February 27, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of |
|
| February 13, 2025 |
EX-99.A 2 e664190ex99-a.htm Exhibit A Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of DocGo Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management |
|
| February 13, 2025 |
EX-99.B 3 e664190ex99-b.htm Exhibit B Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934. |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 20, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi |
|
| November 29, 2024 |
DCGO / DocGo Inc. / VASHOVSKY STANLEY - SC 13D/A Activist Investment SC 13D/A 1 schedule13da-svashovsky.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 DOCGO INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086 109 (CUSIP Number) 35 West 35th Street, Floor 6 New York, New York 10001 (844) 443-6246 (Name, Add |
|
| November 14, 2024 |
DCGO / DocGo Inc. / Flynn James E Passive Investment SC 13G/A 1 e664029sc13ga-docgo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * DocGo Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) September 30, 2024 (Dat |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| November 7, 2024 |
Exhibit 99.1 DocGo Announces Third Quarter 2024 Results Company Significantly Expands Operations on the West Coast to Support New Payer Programs, Increases Full-Year Guidance for Cash Flow from Operations Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, November 7, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technolog |
|
| November 7, 2024 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| September 30, 2024 |
Consulting Agreement, dated September 27, 2024, by and between the Company and Steven Katz Exhibit 10.2 TRANSITION CONSULTING AGREEMENT This TRANSITION CONSULTING AGREEMENT (this “Agreement”) is entered into by and between DocGo Inc., a Delaware corporation (the “Company”), and Steven Katz (“Consultant”). Consultant and the Company are each referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, Consultant has resigned as a member of the Board of Directors (the “Boar |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 25, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 30, 2024 |
Exhibit 10.1 AMENDED AND RESTATED INDEMNIFICATION AGREEMENT This Amended and Restated Indemnification Agreement (this “Agreement”) is entered into as of the date last signed below (the “Effective Date”) by and between DocGo Inc., a Delaware corporation (the “Company”), and the undersigned (the “Indemnitee”). RECITALS WHEREAS, the Board of Directors has determined that the inability to attract and |
|
| September 30, 2024 |
DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board Exhibit 99.1 DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board NEW YORK, September 30, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced the appointment of Stephen K. Klasko, M.D., M.B.A as the new independent, non-executive Chair of its Board of Directors, effective October 1, |
|
| August 7, 2024 |
Second Amendment to Credit Agreement, dated May 7, 2024, by and Exhibit 10.2 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of May 7, 2024 (this “Amendment”), is by and among DOCGO INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and CITIBANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”), Swingline Lender and L/C Issuer. Capitalized ter |
|
| August 7, 2024 |
Non-GAAP Financial Information Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor |
|
| August 7, 2024 |
Exhibit 99.1 DocGo Announces Strong Second Quarter 2024 Results Company Raises Cash Flow From Operations Guidance to $80-$90 Million, Reiterates 2024 Revenue Guidance of $600-$650 Million and Adjusted EBITDA1 Guidance of $65-$75 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time (Note Corrected Call Information Below) NEW YORK, NY, August 7, 2024 – DocGo Inc. (Nas |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 18, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| June 5, 2024 |
United States securities and exchange commission logo June 5, 2024 Lee Bienstock Chief Executive Officer DocGo Inc. |
|
| May 24, 2024 |
DocGo Inc. 35 West 35th Street, Floor 6 New York, New York 10001 DocGo Inc. 35 West 35th Street, Floor 6 New York, New York 10001 May 24, 2024 VIA EDGAR Christie Wong Michael Fay U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: DocGo Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 28, 2024 Form 8-K dated February 28, 2024 |
|
| May 8, 2024 |
Exhibit 99.1 DocGo Announces Strong First Quarter 2024 Results Company Reports First Quarter Net Income of $10.6 Million and Record Adjusted EBITDA1 of $24.1 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, May 8, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today anno |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2024 |
Exhibit 10.3 Ely D. Tendler Strategic & Legal Services, PLLC Guidance through Experience April 18, 2024 CONFIDENTIAL Lee Bienstock, CEO Norm Rosenberg, CFO DocGo Inc. 35 West 35th Street New York, New York 10001 Re: Amended and Restated Engagement Letter Dear Lee and Norm, It has been our pleasure to work with Ambulnz, Inc. and DocGo Inc. (“DocGo”) these past eight-and-a-half years, and we look fo |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission |
|
| April 30, 2024 |
United States securities and exchange commission logo April 30, 2024 Lee Bienstock Chief Executive Officer DocGo Inc. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 25, 2024 |
ANNUAL REPORT 2023 LEADING THE PROACTIVE HEALTHCARE REVOLUTIONBOARD OF DIRECTORS EXECUTIVE OFFICERS Steven Katz Chair of the Board of DocGo Inc. |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 8, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| March 8, 2024 |
, by and between the Company and Stan Vashovsky. Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS This SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS (this “Agreement”) is entered into by and between DocGo Inc., a Delaware corporation (the “Company”), and Stan Vashovsky (“Consultant”). Consultant and the Company are each referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, C |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| March 1, 2024 |
DCGO / DocGo Inc. / Hood River Capital Management LLC - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* DOCGO INC. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396 |
|
| February 28, 2024 |
DocGo Announces Record Fourth Quarter and Full-Year 2023 Results Company Updates 2024 Revenue Guidance to $720-$750 Million, Introduces 2024 Adjusted EBITDA Guidance1 of $80-$85 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, February 28, 2024 – DocGo Inc. |
|
| February 28, 2024 |
Exhibit 21.1 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2023 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United States Ambulnz Community Partners Ltd England and Wales |
|
| February 28, 2024 |
Exhibit 4.2 DESCRIPTION OF SECURITIES The following sets forth a summary of the material terms of the securities of DocGo Inc. (“DocGo”) registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including certain provisions of the Delaware General Corporation Law (as the same exists or may hereafter be amended, the “DGCL”), the Second Amended and Re |
|
| February 28, 2024 |
ated August 3, 2023, by and between the Company and Stephen Sugrue. Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of August 3, 2023 (the “Effective Date”), by and between Stephen Sugrue (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). WHEREAS, Executive has been serving as the Chief Compliance Officer of DocGo Inc. pursuant to that certain promotion letter, effective Decemb |
|
| February 28, 2024 |
(incorporated by reference to Exhibit 97.1 of the Company Exhibit 97.1 DOCGO INC. COMPENSATION RECOUPMENT (CLAWBACK) POLICY (Effective November 15, 2023) Recoupment of Incentive-Based Compensation It is the policy of DocGo Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securi |
|
| February 28, 2024 |
Exhibit 10.17 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR PERFORMANCE STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the target number of performance stock units (“PSUs”) specified below (the “Award”) as performance-based Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each |
|
| February 14, 2024 |
DCGO / DocGo Inc. / Hood River Capital Management LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* DOCGO INC. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 12, 2024 |
DCGO / DocGo Inc. / Flynn James E Passive Investment SC 13G/A 1 e619243sc13ga-docgo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * DocGo Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2023 (Date |
|
| January 31, 2024 |
DocGo Announces Share Buyback Program Exhibit 99.1 DocGo Announces Share Buyback Program NEW YORK, NY, January 31, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that its Board of Directors has approved a new share repurchase program pursuant to which DocGo may purchase up to $36 million of its common stock during a 6-month period ending Jul |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| January 31, 2024 |
.A., as administrative agent (incorporated by reference to Exhibit 10.1 Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of January 30, 2024 (this “Amendment”), is by and among DOCGO INC., a Delaware corporation (the “Borrower”) and CITIBANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”), Swingline Lender and L/C Issuer. Capitalized terms used herein and not otherwise defined herein shal |
|
| January 29, 2024 |
DCGO / DocGo Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us2560861096012924.txt us2560861096012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) DOCGO INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 256086109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 16, 2024 |
DocGo Provides Additional Information to Refute Misleading Short Seller “Report” DocGo Provides Additional Information to Refute Misleading Short Seller “Report” NEW YORK – (Business Wire) – January 16, 2024 – As previously disclosed in our press release dated January 10, 2024, DocGo Inc. |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 16, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| January 10, 2024 |
DocGo Rejects Short Seller Report and Releases Preliminary 2024 Revenue Guidance DocGo Rejects Short Seller Report and Releases Preliminary 2024 Revenue Guidance NEW YORK – (Business Wire) – January 10, 2024 – DocGo Inc. |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| November 6, 2023 |
Exhibit 99.1 DocGo Announces Record Third Quarter 2023 Results Company Raises 2023 Revenue Guidance to $615-$625 Million, up From a Previous Range of $540-$550 Million And Increases Adjusted EBITDA1 Guidance to $50-$55 Million, up From a Previous Range of $48-$53 Million Management to Host Conference Call and Webcast Today at 5:00 p.m. EDT NEW YORK, NY, November 6, 2023 – DocGo Inc. (Nasdaq: DCGO) |
|
| November 6, 2023 |
, 2023, by and between the Company and Lee Bienstock. Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 2, 2023 (the “Effective Date”), by and between Lee Bienstock (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). WHEREAS, Executive was serving as the President and Chief Operating Officer of the Company pursuant to that certain offer letter, effective |
|
| November 6, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DOCGO INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of DocGo Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section 1.2 Other Offices. The Corpo |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 24, 2023 |
Exhibit 99.1 KATHY HOCHUL Governor BARBARA C. GUINN Acting Commissioner October 10, 2023 Mr. George Sarkissian Chief of Staff NYC Housing and Development 100 Gold Street New York, NY 10038 Dear Mr. Sarkissian: The New York State Office of Temporary and Disability Assistance (OTDA) has completed a review of the provisions of services to individuals placed by New York City in temporary housing in ho |
|
| October 24, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 10, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| October 18, 2023 |
DCGO / DocGo Inc / Flynn James E Passive Investment SC 13G 1 e619014sc13g-docgo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * DocGo inc. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) October 9, 2023 (Date of Ev |
|
| October 13, 2023 |
Exhibit 10.1 SEPARATION AND TRANSITION SERVICES AGREEMENT This SEPARATION AND TRANSITION SERVICES AGREEMENT (this “Agreement”) is entered into on this 11th day of October, 2023 by and between DocGo, Inc. (the “Company”) and Anthony Capone (“Executive”). Executive and the Company are each referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, Executive resigned his employment w |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 11, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 6, 2023 |
Exhibit 99.1 ADOLFO CARRIÓN JR. Commissioner Office of the Commissioner 100 Gold Street New York, N.Y. 10038 September 6, 2023 Anthony Capone Chief Executive Officer Rapid Reliable Testing NY, LLC (d/b/a DocGo) 35 West 35th Street New York, New York 10001 Re: Rapid Reliable Testing NY LLC Contract #20248801671 Dear Mr. Capone, I refer to the letter received by my office yesterday from New York Cit |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| August 8, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 8, 2023 |
DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR RESTRICTED STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the number of Restricted Stock Units (the “RSUs”) specified below (the “Award”) under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each RSU represents the right to receive one share of Common Stock, |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 7, 2023 |
Exhibit 99.1 DocGo Announces Record Second Quarter 2023 Results Company Raises 2023 Revenue Guidance To $540-$550 Million Increases Adjusted EBITDA1 Guidance To $48-$53 Million NEW YORK, NY, August 7, 2023 – DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services today announced financial and operating results for the quarter ended June 30, 2023. Q2 2023 Financial Highlig |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 20, 2023 |
Exhibit 99.1 1 01 02 03 04 Proactive Health Care Revolution 05 06 07 08 Excellence In Operations Care Delivery Growth Trajectory Clinical Excellence Q&A Technology Executing Our Vision AGENDA Cautionary Note Regarding Forward - Looking Statements This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of t |
|
| May 9, 2023 |
Offer Letter by and between DocGo Inc. and Lee Bienstock. Exhibit 10.1 35 West 35th Street 6th FL New York, NY 10001 Lee Bienstock Dear Lee, Congratulations! We are pleased to offer you the position of Chief Operating Officer for DocGo, Inc. We're just a few formalities away from getting down to work. Please take the time to review our formal offer. It includes important details about your compensation, benefits and the terms and conditions of your antic |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-39618 DocGo In |
|
| May 8, 2023 |
Exhibit 99.1 DocGo Announces First Quarter 2023 Results Company Reiterates 2023 Revenue Guidance of $500-$510 million and Adjusted EBITDA1 Guidance of $45-$50 million NEW YORK, NY, May 8th, 2023 – DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services today announced financial and operating results for the quarter ended March 31, 2023. Q1 2023 Financial Highlights ● Tota |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| April 26, 2023 |
ANNUAL REPORT 2022BOARD OF DIRECTORS EXECUTIVE OFFICERS Stan Vashovsky Co-Founder and Chairman of the Board DocGo Inc. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission file num |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 14, 2023 |
Exhibit 4.2 DESCRIPTION OF SECURITIES The following sets forth a summary of the material terms of DocGo Inc.’s (“DocGo”) securities, including certain provisions of the Delaware General Corporation Law (as the same exists or may hereafter be amended (the “DGCL”)), the Second Amended and Restated Certificate of Incorporation of DocGo (the “Charter”) and the Amended and Restated Bylaws of DocGo (the |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39618 DocGo Inc. (Exa |
|
| March 14, 2023 |
Exhibit 10.12 EMPLOYEE FORM DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR INCENTIVE STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo, Inc. (the “Company”), hereby grants to Participant named below the Incentive Stock Option (the “Option”) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specifi |
|
| March 14, 2023 |
Exhibit 10.11 EMPLOYEE FORM DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”), hereby grants to Participant named below the Nonqualified Stock Option (the “Option”) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each sp |
|
| March 14, 2023 |
Exhibit 21 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2022 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF PR Ambulnz, LLC Puerto Rico, United States Territory AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United S |
|
| March 14, 2023 |
Exhibit 10.10 DIRECTOR FORM DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR RESTRICTED STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the ”Company”) hereby grants to the Participant named below the number of Restricted Stock Units (the “RSUs”) specified below (the “Award”) under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each RSU represents the right to receive |
|
| March 13, 2023 |
Exhibit 99.1 DocGo Announces Fourth Quarter and Full-Year 2022 Results 2022 Revenue Increased to $440.5 Million, Versus $318.7 Million in 2021, an Increase of 38% Full Year Revenue up 75% Year-Over-Year Excluding Mass Covid Testing Company introduces Full-Year 2023 Revenue and Adjusted EBITDA1 Guidance of $500-$510 million and $45-$50 million, respectively Company to host investor conference call |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 13, 2023 |
Exhibit 99.2 DocGo Awarded $180M in New Business in the United States, United Kingdom Since January as Demand for Mobile Healthcare Grows Volume of new business demonstrates strong growth across key mobile health, medical transportation service lines March 13, 2023 - (New York, NY) DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services, announced today that since the start of |
|
| February 14, 2023 |
EX-99.B 3 d460148dex99b.htm EX-99.B EXHIBIT B POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENT, that I, Louis M. Bacon, hereby make constitute and appoint each of James E. Kaye and James Danza, acting individually, as my agent and attorney-in-fact for the purpose of executing in my name (a) in my personal capacity or (b) in my capacity as Chairman and Chief Executive Officer of each of Moore Capita |
|
| February 14, 2023 |
EX-99.A 2 d460148dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Amendment No. 2 to Schedule 13G with respect to the Common stock, par value $0.0001 per share of DocGo Inc., dated as of February 14, 2023, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of |
|
| February 14, 2023 |
DCGO / DocGo Inc / MOORE CAPITAL MANAGEMENT, LP - SC 13G/A Passive Investment SC 13G/A 1 d460148dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| February 3, 2023 |
DCGO / DocGo Inc / BlackRock Inc. Passive Investment us2560861096020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) DOCGO INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 256086109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 25, 2023 |
DCGO / DocGo Inc / Hood River Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DOCGO INC. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 13, 2023 |
Up to 17,778,588 Shares of Common Stock Prospectus Supplement No. 1 (to prospectus dated December 29, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 17,778,588 Shares of Common Stock This prospectus supplement no. 1 is being filed to update and supplement the prospectus dated December 29, 2022 (the “Prospectus”) related to the offer and sale, from time to time, by the Selling Securityholders (as defined in the |
|
| January 3, 2023 |
Up to 17,778,588 Shares of Common Stock 424B3 1 ea171102-424b3docgo.htm PROSPECTUS PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 17,778,588 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of up to 17,778,588 shares of our Common Stock. We will not receive any proceeds from the sale of shares of Common Stock by t |
|
| December 29, 2022 |
DocGo Announces Stan Vashovsky to Continue to Serve as Chairman of its Board of Directors Exhibit 99.1 DocGo Announces Stan Vashovsky to Continue to Serve as Chairman of its Board of Directors NEW YORK (December 29, 2022) ? (Business Wire) ? DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that its co-founder and current Chairman of the Board and Chief Executive Officer Stan Vashovsky will continue to serve as non-executive Chairman of |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 23, 2022 |
As filed with the Securities and Exchange Commission on December 23, 2022 As filed with the Securities and Exchange Commission on December 23, 2022 Registration No. |
|
| December 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) DocGo Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward |
|
| November 14, 2022 |
Exhibit 99.1 DocGo Appoints Veteran Technology Human Resources Executive Vina Leite, MS, to its Board of Directors and Announces Key Leadership Promotions NEW YORK (Nov. 14, 2022) – (Business Wire) – DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced that it has appointed veteran human resources executive Vina Leite, MS, to its Board of Directors. Ms. Lei |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 10, 2022 |
Prospectus Supplement No. 11 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 11 is being filed to update and supplement the prospectus dated March 22, 2022 (the “Prospe |
|
| November 10, 2022 |
424B3 1 ea168325-424b3docgo.htm PROSPECTUS SUPPLEMENT NO. 12 Prospectus Supplement No. 12 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 12 is being filed to update an |
|
| November 10, 2022 |
Prospectus Supplement No. 13 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 13 is being filed to update and supplement the prospectus dated March 22, 2022 (the “Prospe |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39618 DocGo |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 7, 2022 |
Exhibit 99.1 DocGo Announces Strong Third Quarter 2022 Results Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance Co-founder and CEO Stan Vashovsky announces his retirement effective December 31st; DocGo President Anthony Capone named new CEO; Mr. Vashovsky will consult with the Company through 2023 to assist with the transition C |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 2, 2022 |
Exhibit 10.1 Execution Copy CREDIT AGREEMENT Dated as of November 1, 2022 among DOCGO INC., as the Borrower, THE SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, CITIBANK, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, BANK OF THE WEST, as Documentation Agent, and THE LENDERS PARTY HERETO ************************************************ CITIBANK, N.A., as Sole Lead Ar |
|
| November 2, 2022 |
Exhibit 99.1 DocGo Announces $90 Million Line of Credit with Citibank, N.A. Available funds to be used for opportunistic M&A and working capital as needed NEW YORK (Nov. 2, 2022) ? (Business Wire) ? DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced that it has entered into a $90 million secured line of credit (LOC) with Citibank, N.A. as the Administrati |
|
| August 29, 2022 |
Prospectus Supplement No. 10 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 10 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospe |
|
| August 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 16, 2022 |
Prospectus Supplement No. 9 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 9 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| August 16, 2022 |
DocGo Announces Redemption of All Outstanding Warrants Exhibit 99.1 FOR IMMEDIATE RELEASE? DocGo Announces Redemption of All Outstanding Warrants NEW YORK ? August 15, 2022 ? DocGo Inc. , a leading provider of last-mile mobile health services and integrated ambulance medical transportation solutions (Nasdaq: DCGO), announced today that it will redeem all of its outstanding warrants (the ?Public Warrants?) to purchase shares of DocGo?s common stock, pa |
|
| August 16, 2022 |
NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 256086117) Exhibit 99.2 August 15, 2022 NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 256086117) Dear Warrant Holder, DocGo Inc. (the ?Company?) hereby gives notice that it is redeeming, at 5:00 p.m. New York City time on September 16, 2022 (the ?Redemption Date?), all of the Company?s outstanding Warrants (as defined in the Warrant Agreement (defined below)) (the ?Warrants?) to purchase shares of |
|
| August 10, 2022 |
Prospectus Supplement No. 8 Filed Pursuant to Rule 424(b)(3) (to prospectus dated March 22, 2022) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 8 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| August 10, 2022 |
Prospectus Supplement No. 7 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 7 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39618 DocGo In |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 8, 2022 |
Exhibit 99.1 DocGo Announces Strong Second Quarter 2022 Results Q2 Revenue of $109.5 Million Up 76% Year-Over-Year; Company Raises Full-Year 2022 Guidance NEW YORK, NY, August 8, 2022 - DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced financial and operating results for the second quarter ending June 30, 2022. Second Quarter Financial Highlights ? |
|
| August 8, 2022 |
Prospectus Supplement No. 6 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 6 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| July 28, 2022 |
Prospectus Supplement No. 5 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 5 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| June 24, 2022 |
Prospectus Supplement No. 4 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 4 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| June 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 24, 2022 |
DocGo Announces Share Repurchase Program of Up To $40 Million Exhibit 99.1 DocGo Announces Share Repurchase Program of Up To $40 Million May 24, 2022 ? (New York, NY) ? DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services and integrated medical transportation solutions, announced today that its Board of Directors has authorized a share repurchase program pursuant to which the Company may purchase up to $40 million of its Common Stock. |
|
| May 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 12, 2022 |
Prospectus Supplement No. 3 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 3 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| May 10, 2022 |
Exhibit 99.1 DocGo Announces Strong First Quarter 2022 Results Q1 Revenue of $118 Million Up 137% Over Comparable Prior Year Period Bolsters Senior Staff, Expands Market Footprint NEW YORK, NY, May 9, 2022 - DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services and integrated medical transportation solutions, today announced financial and operating results for the first quart |
|
| May 10, 2022 |
Form of Grant Notice for Incentive Stock Options Exhibit 10.2 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR INCENTIVE STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the ?Company?), hereby grants to Participant named below the Incentive Stock Option (the ?Option?) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, and up |
|
| May 10, 2022 |
DocGo Inc. 2021 Stock Incentive Plan Exhibit 10.4 DOCGO, INC. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this DocGo, Inc. 2021 Stock Incentive Plan (the ?Plan?) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of DocGo, Inc. (the ?Company?) and its stockholders by providing stock-based compensation. The objectives of the Plan are to attract and retain th |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-39618 DocGo In |
|
| May 10, 2022 |
Form of Grant Notice for Nonqualified Stock Options Exhibit 10.1 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the ?Company?), hereby grants to Participant named below the Nonqualified Stock Option (the ?Option?) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, |
|
| May 10, 2022 |
Form of Restricted Stock Unit Grant Notice and Agreement Exhibit 10.3 RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT DocGo Inc. (the ?Company?), pursuant to its 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time, the ?Plan?), hereby grants to Holder the number of the number of Restricted Stock Units set forth below, each Restricted Stock Unit being a notional unit representing the right to receive one share |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ??? ? ? Preliminary Proxy Statement ??? ? ? Confidential, for Use of the Commission Only (as |
|
| April 4, 2022 |
Prospectus Supplement No. 2 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 2 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 30, 2022 |
Prospectus Supplement No. 1 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 1 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| March 24, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 PROSPECTUS Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of: (i) up to 22,223,858 shares of our Common Stock and ( |
|
| March 16, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services NEW YORK, March 14, 2022?DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Comm |
|
| March 15, 2022 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following sets forth a summary of the material terms of our securities, including certain provisions of Delaware law and of the Second Amended and Restated Certificate of Incorporation (the ?Charter?) of DocGo Inc. (?DocGo?), the Amended and Restated Bylaws of DocGo (the ?Bylaws?) and the Warrant Agreement, dated October 14, 2020, by and between DocGo (fka |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39618 DocGo Inc. (Exa |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 14, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services NEW YORK, March 14, 2022?DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 14, 2022 |
Exhibit 99.1 DocGo Announces Record Fourth Quarter and Full Year 2021 Results Q4 and full year revenue increased 289% and 239%, respectively, over comparable prior year periods Positive adjusted EBITDA and net income for both the quarter and full year NEW YORK, NY, March 14, 2022 - DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services and integrated medical transportation sol |
|
| February 14, 2022 |
DCGO / DocGo Inc / MOORE CAPITAL MANAGEMENT, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
DCGO / DocGo Inc / Radcliffe Capital Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* DocGo Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 20 |
|
| February 10, 2022 |
DCGO / DocGo Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - DOCGO INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DocGo Inc. (formerly known as Motion Acquisition Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| February 4, 2022 |
DCGO / DocGo Inc / Weiss Asset Management LP Passive Investment CUSIP NO. 256086109 SCHEDULE 13G/A PAGE 1 OF 10 PAGES =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DOCGO INC. (FORMERLY KNOWN AS MOTION ACQUISITION CORP) - (Name of Issuer) Common Stock, par value $0.0001 per share - |
|
| February 3, 2022 |
Prospectus Supplement No. 1 (to prospectus dated January 3, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 28,234,175 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 1 is being filed to update and supplement information contained in the prospectus dated Jan |
|
| February 2, 2022 |
DCGO / DocGo Inc / Linden Capital L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| January 28, 2022 |
Exhibit 99.1 DocGo Announces Record Preliminary Fourth Quarter 2021 Revenue Full year and fourth quarter revenue of $305.0 million and $107.8 million, respectively, more than triple versus prior year periods January 28, 2022 - (New York, NY) ?DocGo, (Nasdaq: DCGO), a leading provider of last-mile mobile health services and integrated medical mobility solutions, announced today select preliminary u |
|
| January 11, 2022 |
As filed with the Securities and Exchange Commission on January 11, 2022 As filed with the Securities and Exchange Commission on January 11, 2022 Registration No. |
|
| January 3, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 PROSPECTUS Up to 28,234,175 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of: (i) up to 28,234,175 shares of our Common Stock and ( |
|
| December 29, 2021 |
December 29, 2021 VIA EDGAR Anuja Majmudar Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, NE Washington, D. |
|
| December 15, 2021 |
CORRESP 1 filename1.htm Evan M. D’Amico Direct: +1 202.887.3613 Fax: +1 202.530.4255 [email protected] December 15, 2021 VIA EDGAR Anuja Majmudar Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, NE Washington, D.C. 20549-3561 Re: DocGo Inc. Registration Statement on Form S-1 Filed November 24, 2021 File No. 333-261363 Dear Ms. |
|
| December 15, 2021 |
As filed with the Securities and Exchange Commission on December 15, 2021 As filed with the Securities and Exchange Commission on December 15, 2021 Registration No. |
|
| December 6, 2021 |
United States securities and exchange commission logo December 6, 2021 Stan Vashovsky Chief Executive Officer DocGo Inc. |
|
| December 1, 2021 |
Exhibit 99.1 DocGo Announces Increase in Full-Year 2021 Guidance Annual revenues expected to reach over $290 million, Adjusted EBITDA of at least $12 million December 1, 2021 - (New York, NY) ? DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced today that it is updating and increasing its full-year 2021 guidance for both |
|
| December 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to MOTION ACQUISITION CORP. (Exact Name of |
|
| November 24, 2021 |
As filed with the Securities and Exchange Commission on November 24, 2021 As filed with the Securities and Exchange Commission on November 24, 2021 Registration No. |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DOCGO INC. (Exact Name of Registrant as Specifie |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2021 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 15, 2021 |
Exhibit 99.1 Ambulnz, Inc. and Subsidiaries CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIODS ENDED SEPTEMBER 30, 2021 and 2020 Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months and Nine Months Ended September 30, 2021 and Septemb |
|
| November 15, 2021 |
DOCGO’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 DOCGO’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of DocGo’s financial condition and results of operations should be read in conjunction with its consolidated statements, the accompanying notes, and other financial information included elsewhere in this current report on Form 8-K filing. This discussion |
|
| November 15, 2021 |
DCGO / DocGo Inc / VASHOVSKY STANLEY - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No.)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 DOCGO INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 256086 109 (CUSIP Number) 35 West 35th Street, Floor 5 New York, New York 10001 (888) 927-7296 (Name, Address and Telephone Number of Person Authorized to |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DOCGO INC. (Exact Name of Registrant as Specified |
|
| November 15, 2021 |
DCGO / DocGo Inc / MOORE CAPITAL MANAGEMENT, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) November 5, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 (November 5, 2021) DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) ( |
|
| November 15, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K/A to which this Unaudited Pro Forma Condensed Combined Financial Information is attached (the ?Form 8-K/A?) and, if not defined in the Form 8-K/A, the proxy statement/consent solicitation/prospectus (th |
|
| November 12, 2021 |
Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of November 5, 2021, by and between Anthony Capone (?Executive?) and Motion Acquisition Corp., a Delaware corporation (the ?Company?). WHEREAS, Executive has been serving as the Chief Technology Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (?Ambulnz?) pursu |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2021 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 12, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K to which this Unaudited Pro Forma Condensed Combined Financial Information is attached (the ?Form 8-K?) and, if not defined in the Form 8-K, the proxy statement/consent solicitation prospectus filed wit |
|
| November 12, 2021 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MOTION ACQUISITION CORP. (a Delaware corporation) Motion Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is ?Motion Acquisition Corp.,? and is changing its name to ?DocGo Inc.? pursuant to this Secon |
|
| November 12, 2021 |
EX-14.1 12 ea150082ex14-1docgoinc.htm DOCGO INC. CODE OF BUSINESS CONDUCT AND ETHICS Exhibit 14.1 CODE OF BUSINESS CONDUCT AND ETHICS (dated November 5, 2021) I. INTRODUCTION This Code of Business Conduct and Ethics (this “Code”) provides a general statement of the expectations of DocGo Inc. (the “Company” or “DocGo”) regarding the ethical standards to which each director, officer and employee sho |
|
| November 12, 2021 |
Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of November 5, 2021, by and between Andre Oberholzer (?Executive?) and Motion Acquisition Corp., a Delaware corporation (the ?Company?). WHEREAS, Executive has been serving as the Chief Financial Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (?Ambulnz?) purs |
|
| November 12, 2021 |
Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of November 5, 2021, by and between Stan Vashovsky (?Executive?) and Motion Acquisition Corp., a Delaware corporation (the ?Company?). WHEREAS, Executive has been serving as the Chief Executive Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (?Ambulnz?); WHERE |
|
| November 12, 2021 |
EX-10.11 11 ea150082ex10-11docgoinc.htm STOCK ESCROW AGREEMENT, DATED AS OF NOVEMBER 5, 2021, BY AND AMONG MOTION ACQUISITION CORP., MOTION ACQUISITION LLC, AND CONTINENTAL STOCK & TRANSFER COMPANY Exhibit 10.11 STOCK ESCROW AGREEMENT STOCK ESCROW AGREEMENT, dated as of November 5, 2021 (“Agreement”), by and among Motion Acquisition Corp. (to be renamed DocGo Inc.), a Delaware corporation (“Parent |
|
| November 12, 2021 |
Exhibit 10.10 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is entered into as of November , 2021 (the ?Effective Date?) by and between DocGo Inc., a Delaware corporation (the ?Company?), and the undersigned (the ?Indemnitee?). RECITALS WHEREAS, the Board of Directors has determined that the inability to attract and retain qualified persons as directors and of |
|
| November 12, 2021 |
EX-16.1 13 ea150082ex16-1docgoinc.htm LETTER FROM WITHUMSMITH+BROWN, PC ADDRESSED TO THE SECURITIES AND EXCHANGE COMMISSION, DATED AS OF NOVEMBER 5, 2021 Exhibit 16.1 November 10, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read Docgo Inc. (formerly known as Motion Acquisition Corp.) statements include |
|
| November 12, 2021 |
Exhibit 4.3 SPECIMEN COMMON STOCK CERTIFICATE NUMBER NUMBER OF SHARES OF COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 256086 109 DOCGO INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE OF $0.0001 PER SHARE, OF DOCGO INC. (THE ?COMPANY?) transferable on the books of the |
|
| November 12, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DOCGO INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of DocGo Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, excep |
|
| November 12, 2021 |
EX-10.9 9 ea150082ex10-9docgoinc.htm NEW EXECUTIVE AGREEMENT, EFFECTIVE NOVEMBER 5, 2021, BY AND BETWEEN MOTION ACQUISITION CORP. AND NORM ROSENBERG Exhibit 10.9 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 5, 2021, by and between Norman Rosenburg (“Executive”) and Motion Acquisition Corp., a Delaware corporation (the “Company” |
